Reference
Merchant S, et al. Budget Impact Analysis of Tapentadol Extended Release for the Treatment of Moderate to Severe Chronic Noncancer Pain. Clinical Therapeutics : 13 Apr 2013. Available from: URL: http://dx.doi.org/10.1016/j.clinthera.2013.03.016
Rights and permissions
About this article
Cite this article
Tapentadol ER has positive impact on health plan budgets. PharmacoEcon Outcomes News 678, 9 (2013). https://doi.org/10.1007/s40274-013-0404-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0404-8